NY-ESO-1-specific T-cells - Adaptimmune

Drug Profile

NY-ESO-1-specific T-cells - Adaptimmune

Alternative Names: '794; GSK 3377794; NY-ESO SPEAR T-cell therapy; NY-ESO TCR therapeutic; NY-ESO-1 T cell receptor; NY-ESO-1/LAGE-1-modified T-cells; NY-ESO-1/LAGE-1-specific T-cells - Adaptimmune; NY-ESO-1c259T

Latest Information Update: 12 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Adaptimmune
  • Developer Adaptimmune; GlaxoSmithKline; Merck & Co
  • Class Antineoplastics; Gene therapies; T lymphocyte cell therapies
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Synovial sarcoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Gastrointestinal cancer; Malignant melanoma; Multiple myeloma; Ovarian cancer
  • Phase I/II Liposarcoma; Non-small cell lung cancer; Synovial sarcoma
  • No development reported Liver cancer; Prostate cancer

Most Recent Events

  • 07 Sep 2017 GlaxoSmithKline exercises the option to obtain an exclusive global license from Adaptimmune for NY-ESO SPEAR T-cell therapy (GSK 3377794)
  • 05 Jun 2017 Updated efficacy and adverse events data from a phase I/II trial in Synovial sarcoma presented at the Annual Meeting of American Society of Clinical Oncology (ASCO-2017)
  • 25 May 2017 Phase-I clinical trials in Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA (IV) (NCT03168438)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top